Keratoconjunctivitis Sicca: Clinical Trials

85 trials for Keratoconjunctivitis Sicca, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

74 completed, 5 withdrawn, 4 unknown, 1 not yet recruiting. 26 Phase 2, 23 Phase 3, 20 Not applicable, 11 Phase 4, 5 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 226Completed 23, Not yet recruiting 1, Unknown 1, Withdrawn 1
Phase 323Completed 22, Unknown 1
Not applicable20Completed 17, Terminated 1, Unknown 1, Withdrawn 1
Phase 411Completed 8, Withdrawn 3
Phase 15Completed 4, Unknown 1

Follow Keratoconjunctivitis Sicca: new trials by email Literature Review of Keratoconjunctivitis Sicca trials Research Report on Keratoconjunctivitis Sicca

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease
BRM421 Ophthalmic Solution, 0.03%, Artificial Tear, BRM421 Ophthalmic Solution, 0.06% - Dry Eye Disease (DED), Keratoconjunctivitis Sicca
Phase 2Not yet recruitingBRIM Biotechnology Inc.992025-12-012025-10-20
Tolerability and Efficacy Study of Reinnerva/Lubristil+G vs Vismed
Reinnerva/Lubristil +G sterile eye drops (artificial tears), Vismed sterile eye drops (artificial tears) - Keratoconjunctivitis Sicca
Not applicableCompletedMedivis SRL402025-06-092026-02-19
Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye Disease
INV-102, Vehicle - Dry Eye Disease
Phase 2CompletedInvirsa, Inc.1092024-03-272026-09-18
Vizol S DIGI EYE Efficacy and Safety Study in Patients With Dry Eye
Vizol S DIGI EYE eye drops, 0,9% saline solution, eye drops - Dry Eye Disease (DED)
Phase 3CompletedJadran Galenski laboratorij d.d.862024-03-202025-07-03
Medical vs Acupuncture for Dry Eye
Artificial tears, Traditional Chinese Medicine Acupuncture - Dry Eye, Acupuncture
Not applicableCompletedNadide Koca902024-01-152025-09-22
Phase 4 Study Evaluating the Safety of the Nasal Guide With Tyrvaya
Nasal Guide - Dry Eye, Keratoconjunctivitis Sicca
Phase 4CompletedOyster Point Pharma, Inc.302023-06-142025-05-06
Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B
punctum plug insertion, Eye Drops, Lubricant - Dry Eye, Keratoconjunctivitis Sicca
Phase 1UnknownEximore Ltd.202022-09-292023-09-07
Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease
INV-102, Vehicle - Dry Eye Disease
Phase 1 / Phase 2CompletedInvirsa, Inc.842022-08-302026-09-18
Vizol S Lipid Balance Efficacy and Safety Study in Patients With Dry Eye
Vizol S LIPID BALANCE eye drops, ophthalmic saline eye drops - Dry Eye Disease
Phase 3CompletedJadran Galenski laboratorij d.d.642022-06-012024-03-21
Safety Study of Tivanisiran to Treat Dry Eye
Tivanisiran sodium ophthalmic solution, Vehicle ophthalmic solution - Dry Eye Disease
Phase 3CompletedSylentis, S.A.3012022-03-242026-09-09
Sphenopalatine Ganglion Stimulation for Ocular and Oral Dryness
Osteopathic protocol of Sphenopalatine Ganglion Stimulation - Dry Eye Disease, Xerostomia
Not applicableCompletedInstituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA302022-01-152024-11-01
Levocarnitine for Dry Eye in Sjogren's Syndrome
Levocarnitine, Placebo - Sjogren's Syndrome, Keratoconjunctivitis Sicca
Phase 2CompletedVanderbilt University Medical Center152021-11-172025-12-04
Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome
Tivanisiran sodium ophthalmic solution, Vehicle ophthalmic solution - Dry Eye Disease, Sjögren Syndrome
Phase 3CompletedSylentis, S.A.2032021-05-252024-02-20
Treatment of Dry Eye Disease Using Pro-ocular™ - A Proof of Concept, Safety, and Efficacy Study
Pro-ocular™ Topical Gel, Placebo Topical Gel - Dry Eye Syndrome, Keratoconjunctivitis Sicca
Phase 2UnknownPharmaDax Inc.802021-05-202021-05-14
Differential Diagnosis of Sjögren's Versus Non-Sjögren's Dry Eye
Questionnaires, Tear fluid sampling, Impression Cytology - Keratoconjunctivitis Sicca, Dry Eye Syndromes
CompletedJohns Hopkins University922021-01-112023-01-05
Pilot Study to Investigate the Feasibility, Reliability and Efficacy of Utilizing OCT to Automate PROSE Fitting
Ocular surface optical coherence tomography - Keratoconus, Ocular Surface Disease
Not applicableCompletedBoston Sight112020-12-152023-10-27
Mesenchymal Stem Cell Therapy of Dry Eye Disease in Patients With Sjögren's Syndrome
ASCs, Cryostor CS10 - Keratoconjunctivitis Sicca, in Sjogren's Syndrome
Phase 2CompletedCopenhagen University Hospital, Rigshospitalet402020-11-032023-03-08
A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease
ECF843, ECF843 vehicle - Dry Eye
Phase 2CompletedNovartis Pharmaceuticals7182020-10-062025-01-28
A Randomized Study of Smile Exercise for Dry Eye
smile exercise, 0.1% sodium hyaluronate eye drop - Dry Eye, Keratoconjunctivitis Sicca
Not applicableCompletedZhongshan Ophthalmic Center, Sun Yat-sen University2992020-07-022024-05-14
Effect of Cequa™ in Subjects With Dry Eye Disease
CequaTM (Cyclosporine 0.09%) ophthalmic solution - Dry Eye Disease
Phase 4CompletedSun Pharmaceutical Industries Limited1352020-06-292024-02-06

Showing 20 of 85. Sign in to see all of them.

Narrower conditions

Dry Eye Syndromes (67)  ·  Sjogren's Syndrome (9)  ·  Xerophthalmia (4)  ·  Corneal Diseases (3)  ·  Hyperemia (3)  ·  Keratitis (3)  ·  Pain (3)  ·  Xerostomia (3)  ·  Conjunctival Diseases (2)  ·  Eye Diseases (2)  ·  Fatigue (2)  ·  Keratoconjunctivitis (2)  ·  Lacrimal Apparatus Diseases (2)  ·  Amaurosis Fugax (1)

Broader conditions

Conjunctivitis (84)  ·  Conjunctival Diseases (83)  ·  Eye Diseases (83)  ·  Keratoconjunctivitis (83)  ·  Lacrimal Apparatus Diseases (83)  ·  Corneal Diseases (82)  ·  Keratitis (82)  ·  Dry Eye Syndromes (18)  ·  Mouth Diseases (11)  ·  Salivary Gland Diseases (11)  ·  Stomatognathic Diseases (11)  ·  Immune System Diseases (10)  ·  Arthritis (9)  ·  Connective Tissue Diseases (9)  ·  Joint Diseases (9)

Interventions

Lubricant Eye Drops (6)  ·  Loteprednol Etabonate (5)  ·  Cyclosporins (4)  ·  rebamipide (4)  ·  Cyclosporine (3)  ·  Ophthalmic Solutions (3)  ·  lifitegrast (3)  ·  CF101 (2)  ·  Carboxymethylcellulose Sodium (2)  ·  Glycerol (2)  ·  Hyaluronic Acid (2)  ·  Sodium Chloride (2)  ·  Acupuncture Therapy (1)  ·  Adrenal Cortex Hormones (1)  ·  Carnitine (1)

Sponsors

Allergan (4)  ·  Oculeve, Inc. (4)  ·  Sun Pharmaceutical Industries Limited (4)  ·  Kala Pharmaceuticals, Inc. (3)  ·  Mimetogen Pharmaceuticals USA, Inc. (3)  ·  Rigel Pharmaceuticals (3)  ·  Can-Fite BioPharma (2)  ·  Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA (2)  ·  Invirsa, Inc. (2)  ·  Jadran Galenski laboratorij d.d. (2)  ·  Kubota Vision Inc. (2)  ·  Ohio State University (2)  ·  Otsuka Pharmaceutical Development & Commercialization, Inc. (2)  ·  Sylentis, S.A. (2)  ·  University of Alabama at Birmingham (2)

Countries

United States (56)  ·  Spain (4)  ·  France (3)  ·  Israel (3)  ·  Denmark (2)  ·  Germany (2)  ·  Serbia (2)  ·  Taiwan (2)  ·  United Kingdom (2)  ·  Austria (1)  ·  Brazil (1)  ·  Chile (1)  ·  China (1)  ·  Hungary (1)  ·  Italy (1)

Top investigators

Gail Torkildsen, MD (4)  ·  Garth Cumberlidge, PhD (2)  ·  Gary Foulks, MD (2)  ·  Robert Shalwitz, MD (2)  ·  Anne Marie Lynge Pedersen, PhD, DDS (1)  ·  Christine Shieh, MD (1)  ·  Daniel B Rootman, MD, MSc (1)  ·  Daniel Brocks, MD (1)  ·  Daniel Magilavy, MD (1)  ·  David Evans, OD (1)  ·  Edward Holland, MD (1)  ·  Esen Akpek, MD (1)

Results publications

PMID 30472141, PMID 15948994, PMID 16021174, PMID 17054241, PMID 20304499, PMID 20631232, PMID 21310379, PMID 22378109, PMID 22511024, PMID 23884332, PMID 24289915, PMID 24695688, PMID 25083776, PMID 25473263, PMID 26733410, PMID 26783543, PMID 27445067, PMID 28736342, PMID 28736344, PMID 29119483, PMID 32826644, PMID 33469259, PMID 33710587, PMID 36729473, PMID 36944128, PMID 39260878, PMID 42837491

NIH funding

R34EY017626 (1)